Welcome to our dedicated page for POINT Biopharma Global news (Ticker: $PNT), a resource for investors and traders seeking the latest updates and insights on POINT Biopharma Global stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect POINT Biopharma Global's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of POINT Biopharma Global's position in the market.
Rhea-AI Summary
Domain Therapeutics (Domain), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), announces the appointments of Michael Gottlieb as Chairman of the Board of Directors and Anthony Johnson, M.D., as President and Chief Executive Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) successfully completed the acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies for cancer treatment. The acquisition was completed through a tender offer and a second-step merger. Lilly acquired approximately 67.97% of POINT's outstanding shares. The acquisition marks Lilly's entry into the next-generation radioligand therapies space, with the goal of bringing new radioligand therapies to cancer patients to improve their outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
-
Rhea-AI Summary
Lantheus Holdings, Inc. (LNTH) and POINT Biopharma Global Inc. (PNT) announced statistically significant topline results from the phase 3 SPLASH study of 177Lu-PNT2002, demonstrating a 29% reduction in the risk of radiographic progression or death in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI). The study met its primary endpoint, with a median radiographic progression-free survival of 9.5 months for patients treated with 177Lu-PNT2002 compared to 6.0 months for patients treated with ARPI in the control arm. The study showed a favorable safety profile and lower toxicity in the 177Lu-PNT2002 arm. Additional data is expected in 2024 prior to the potential submission of a New Drug Application (NDA).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.2%
Tags
Rhea-AI Summary
Eli Lilly and Company (LLY) extends the expiration of the tender offer to acquire all shares of POINT Biopharma Global Inc. (PNT) at $12.50 per share in cash. The offer has been extended until Dec. 22, 2023, to fulfill the minimum tender condition. Approximately 22.81% of the issued and outstanding shares have been tendered as of Dec. 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) extends tender offer to acquire POINT Biopharma Global Inc. (NASDAQ: PNT) for $12.50 per share in cash, without interest. The offer has been extended until Dec. 15, 2023, to satisfy the minimum tender condition. Approximately 24.75% of the issued and outstanding shares have been tendered as of Dec. 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) extends the expiration of the tender offer to acquire all outstanding shares of POINT Biopharma Global Inc. (NASDAQ: PNT) at $12.50 per share in cash. The offer, previously set to expire on Nov. 16, 2023, has been extended to Dec. 1, 2023, to satisfy the minimum tender condition. Regulatory approvals have been obtained, and approximately 26.45% of the outstanding shares have been tendered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) obtains NRC Consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license. This follows the completion of Lilly's tender offer to acquire all POINT's common stock for $12.50 per share in cash. The NRC Consent is the final regulatory approval needed for the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
-
Rhea-AI Summary
POINT Biopharma Global Inc. (NASDAQ: PNT) announced a definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY) for $12.50 per share in cash, totaling $1.4 billion. The acquisition is expected to close near the end of 2023. The PR also includes business updates, financial results, and upcoming milestones for POINT's radiopharmaceutical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
-
Rhea-AI Summary
Eli Lilly and Company (LLY) extends tender offer to acquire POINT Biopharma Global Inc. (PNT) shares at $12.50 per share in cash, with the expiration now set for Nov. 16, 2023. Approximately 14.16% of the outstanding shares have been tendered as of Nov. 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
Rhea-AI Summary
Eli Lilly and Company to acquire POINT Biopharma Global, Inc. for $1.4 billion, expanding its radioligand therapy pipeline for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
POINT Biopharma Global Inc.
Nasdaq:PNT
PNT Rankings
PNT Stock Data
1.33B
87.47M
14.98%
48.91%
2.82%
Pharmaceutical Preparation Manufacturing
Manufacturing
US
Indianapolis
About PNT
a novel, research based biotechnology company focused on the development and commercialization of radiopharmaceutical products to meet unmet patient needs